Cardiovascular Mortality

Reassessing the Role of Steroidal Mineralocorticoid Receptor Antagonists in Dialysis Patients: Safety and Efficacy Insights from a Systematic Review and Meta-Analysis

By MedXY 10/11/2025

Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.

Cardiology Clinical Updates news

Reevaluating Mortality Risks: The Paradox of Low Apolipoprotein B and LDL-Cholesterol Levels in Cardiovascular Health

By MedXY 09/24/2025

This study finds an unexpected association between low levels of apolipoprotein B and LDL-cholesterol with increased all-cause and cardiovascular mortality, highlighting the complex role of lipid markers in mortality risk assessment.

Cardiology news Specialties

Risks and Realities of Withdrawing Heart Failure Medications After Ejection Fraction Improvement

By MedXY 08/17/2025

Withdrawal of renin-angiotensin inhibitors and mineralocorticoid receptor antagonists in patients with heart failure and improved ejection fraction significantly increases 1-year cardiovascular mortality and hospitalization risks; beta-blocker withdrawal shows varied effects based on EF.